Evidence map›Paper›PMID 39116277›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2024

C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation.

Blanca Tarragón, Yonatan Peleg, Geetha Jagannathan, Miroslav Sekulic, Jae-Hyung Chang, David J Cohen, Russell J Crew, Geoffrey K Dube, Hilda E Fernandez, Syed Ali Husain and 9 more

Abstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.Canadian journal of kidney health and disease · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Blanca TarragónDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-1784-6929
Yonatan PelegDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-3569-1270
Geetha JagannathanDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-9567-7756
Miroslav SekulicDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-7938-1816
Jae-Hyung ChangDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-2290-875
David J CohenDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-1227-3252
Russell J CrewDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-6507-8939
Geoffrey K DubeDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-0206-5652
Hilda E FernandezDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-3740-1062
Syed Ali HusainDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-1823-0117
Sumit MohanDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-5305-9685
Heather K MorrisDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-6640-2569
Gerald B AppelDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Paresh JadavDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Dominick SantorielloDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.
Satoru KudoseDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-8396-9877
M Barry StokesDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-0958-7672
Ibrahim BatalDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-0686-5457
Andrew S BombackDivision of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-5449-1667

Funding

Genetics and Immune Predictors for Recurrent Glomerular Diseases in the Kidney AllograftR01DK135671 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ibrahim Batal · 2023 to 2026
$1.5M
National Institute of Diabetes and Digestive and Kidney Diseases,Fundación Alfonso Martín Escudero R01DK135671-01NIDDK NIH HHS R01 DK135671NIDDK NIH HHS R01DK135671-01
6 · The paper itself

Abstract

Background: C3 glomerulopathy (C3G), which encompasses C3GN and dense deposit disease (DDD), results from dysregulation of the alternative complement pathway. Data on disease recurrence after kidney transplantation are limited, and details on histologic features of recurrent C3G are scarce. We aimed to evaluate C3G recurrence in the allograft, with a focus on histologic presentation and progression. Methods: We retrospectively analyzed 18 patients with native kidney failure attributed to C3G (12 C3GN and six DDD), who received a kidney transplant from January 2016 to January 2023. Demographic, genetic, clinical, and histologic data were studied. The NanoString 770 genes PanCancer Immune Profiling Panel was used for transcriptomic analysis. Disease recurrence was the primary outcome. Results: During a median (interquartile range) follow-up period of 37 (18–56) months, C3G recurrence occurred in 16 (89%) patients (11 with C3GN and five with DDD) at a median (interquartile range) of 33 (13–141) days after transplantation. Over a third (38%) of recurrent cases were detected in protocol biopsies, and only 31% of patients presented with >300 mg/g of proteinuria. Recurrence in index biopsies was mainly established through a combination of immunofluorescence and electron microscopy findings, while it showed only subtle histologic alterations and no characteristic transcriptomic signals. Over time, histologic chronicity indices increased, but all the allografts were functioning at the end of follow-up. Patients with recurrence of C3GN and DDD showed overlapping immunofluorescence and electron microscopy findings and had similar recurrence rate and time to recurrence. Conclusions: Most of the patients with native kidney failure attributed to C3G developed disease recurrence very early after kidney transplantation, usually with minimal proteinuria, mild histologic alterations, and favorable short-term allograft survival. Immunofluorescence and electron microscopy played a crucial role in detecting early, subclinical recurrence of C3GN and DDD, which showed significant overlapping features.

Indexed as

Kidney TransplantationRecurrenceAdultBiopsyComplement C3FemaleGlomerulonephritisHumansMaleMiddle AgedTime FactorsComplement C3

Identifiers

PMID39116277
PMCPMC11321730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.